All In Biotech

Drug Trial Radar · NCT01285700

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

Last checked: Nov 20, 2026Latest source record: Sep 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Actual

Start

Jan 2011

Primary completion

Jan 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Zymenex A/SIndustry
Sponsor type
Industry
Collaborators
European Commission
First posted
Jan 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.

Conditions

  • Alpha Mannosidosis

Interventions

  • LamazymDrug

    ERT, infusion weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of Oligosaccharides in urineTime frame: 3 months (interim evaluation) + 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.